Metformine Eg Labo (Metformin Hydrochloride)

Metformin acts mainly by inhibiting hepatic gluconeogenesis, which reduces the amount of glucose released by the liver. It also increases peripheral insulin sensitivity, enhancing glucose uptake in muscle and fat tissue, and modestly decreases intestinal glucose absorption, together improving overall glycaemic control.

The exact dose of Metformine Eg Labo is determined by the prescribing healthcare professional based on the patient’s individual clinical profile, renal function, and glycaemic targets. Dosage may be started low and titrated upward as needed, following established clinical guidelines.

Safety of metformin in pregnancy and lactation has not been fully established. It may be used during pregnancy only if the potential benefit outweighs the risk, and breastfeeding mothers should discuss alternatives with their clinician, as metformin can be excreted in breast milk.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metformin belongs to the biguanide class and is generally preferred as first‑line therapy for type 2 diabetes because it does not cause weight gain and has a low risk of hypoglycaemia compared with sulfonylureas or insulin. It may be combined with other agents when additional glucose lowering is required.

Metformine Eg Labo should be stored at ambient temperature, below 25 °C, in the original container to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiry date printed on the packaging.

The medication is taken orally, usually with meals to minimise gastrointestinal discomfort. Tablets should be swallowed whole with a full glass of water and not crushed or chewed unless otherwise directed by a healthcare professional.

The most serious adverse effect is lactic acidosis, a rare but potentially fatal condition that can occur in patients with severe renal or hepatic impairment, hypoxia, or excessive alcohol intake. Prompt medical attention is required if symptoms such as rapid breathing, muscle pain, or abdominal discomfort develop.

Metformine Eg Labo is contraindicated in individuals with severe renal impairment (eGFR < 30 mL/min/1.73 m²), acute or chronic metabolic acidosis, known hypersensitivity to metformin, or those receiving radiographic contrast studies without adequate renal monitoring.